Last reviewed · How we verify

NCT05975112

The Incidence of Hyperfibrinolysis During Vaginal Delivery and Cesarean Section

Status unknown Last updated 21 March 2024
What this trial tests

trial testing Coagulation tests (TEG, Levels of F1, F2, hs-D-dimer, Plasminogen, PAI 1+2), SpHb before discharge in Hyperfibrinolysis in 780 participants. Status unknown.

Timeline
1 June 2023
Primary endpoint
30 November 2024
17 April 2025

Quick facts

Lead sponsorMedical University of Graz
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment780
Start date1 June 2023
Primary completion30 November 2024
Estimated completion17 April 2025
Sites1 location across Austria

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of Graz

Who can join

18 and older, female only, with Hyperfibrinolysis or Cesarean Section Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to find out if there are common major changes in coagulation immediately after delivery of the newborn during Cesarean (C) -section and vaginal birth.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Non-Invasive Measurement of Serum Haemoglobin for the Detection of Postpartum Anaemia: A Prospective Observational Study.
    Honnef G, Hallmann B, Eichlseder M, Eichinger M, et al · · 2026 · PMID 41976784 · DOI 10.3390/jcm15072483
  2. Hyperfibrinolysis During Caesarean Section and Vaginal Delivery: A Prospective Cross-Sectional Study in the Delivery Room.
    Zoidl P, Honnef G, Eichinger M, Eichlseder M, et al · · 2025 · PMID 41517278 · DOI 10.3390/jcm15010027

Verify or expand the search:

Other Medical University of Graz trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05975112.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing